



PROJECT

RBDCOV

RBD Dimer recombinant protein vaccine against SARSCoV2

The main objective of RBDCOV project is to test the efficacy, tolerability, and safety of two new clinical trials against different variants of COVID-19 (Wuhan and South African/UK) based on the outstanding data generated using a recombinant protein developed by the consortium partners.



"Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them."

13

PARTNERS

5


COUNTRIES

€9M

TOTAL BUDGET

30

MONTHS



**RBDCOV
Project**

IN ONE CLICK

Coordinator HIPRA Scientific	Programme Horizon Europe	Period 2021-2024
	Sector HEALTH	Web www.rbdcov.eu

01
Challenge

Since the publication of the genome sequence of SARS-CoV2, on January 11th, 2020, an endeavour of unprecedented speed and magnitude set out to develop a vaccine against the disease. An ideal SARS-CoV-2 vaccine should meet the following requirements: protect not only from severe disease but also thwart infection in all vaccinated populations, including less immunocompromised individuals, elicit long term memory immune responses after a minimal number of immunizations or booster doses, able to ramp up production to produce billions of doses.

02
Solution

RBDCOV will provide a vaccine that should meet the following requirements: protect not only from severe disease but also thwart infection in all vaccinated populations, including less immunocompromised individuals; elicit long term memory immune responses after a minimal number of immunizations of booster doses; able to ramp up production to produce billions of doses annually and be easily accessible for worldwide vaccination campaigns at an affordable cost and at limited time.

03
Impacts

RBDCOV is an ambitious project that will offer a new tool to control the pandemic in the short-medium and long term. RBDCOV aims to manufacture and test the first recombinant protein-based vaccine to be licensed in Europe beyond the scope of the project. The final formulation of RBDCOV vaccine, the company's experience in the use of highly innovative platforms for the manufacture of vaccines animal vaccine manufacturing and the strong consortium involved in the RBDCOV project will make it feasible to lay the foundation for this challenging goal.